Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to David Ross Camidge

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Camidge, David

One or more keywords matched the following items that are connected to Camidge, David

Item Type	Name
Academic Article	Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies.
Academic Article	Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development.
Academic Article	Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
Academic Article	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Academic Article	The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.
Academic Article	A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers.
Academic Article	Surprised by stage III: unexpected N2 lymph node involvement found during surgery for early-stage NSCLC.
Academic Article	Targeted manipulation of apoptosis in cancer treatment.
Academic Article	Biomarkers are here to stay for clinical research and standard care.
Academic Article	Is FISH floating or still swimming in the lung cancer ocean?
Academic Article	Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Academic Article	Molecular origins of lung cancer: prospects for personalized prevention and therapy.
Academic Article	A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Concept	Biomarkers, Pharmacological
Concept	Biomarkers, Tumor
Concept	Biomarkers
Academic Article	Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
Academic Article	A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Academic Article	NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
Academic Article	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Non-Small Cell Lung Cancer: Results of a Phase I Study.
Academic Article	Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Academic Article	Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.
Academic Article	Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer.
Academic Article	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
Academic Article	Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Academic Article	Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
Academic Article	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Academic Article	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
Academic Article	ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Academic Article	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Academic Article	Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Academic Article	Next-generation ALK inhibitors: is the median the message?
Academic Article	Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer.
Academic Article	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Academic Article	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer.
Academic Article	Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
Grant	A randomized phase II study of erlotinib with or without the anti-IGF-1R monoclon

Search Criteria

Biomarkers